STipe Therapeutics discloses its new Board of Directors along with raising 20m Series A funding co-led by Novo Holdings and Arix Bioscience
– DENMARK, Aarhus – STipe Therapeutics, a company founded to exploit a novel approach to the stimulator of interferon genes Pathway, a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders, has launched today with a EUR 20 million Series A financing round co-led by Novo Holdings and Arix Bioscience plc who were joined by Wellington Partners Life Science V Fund and Sunstone Life Science Ventures A/S.…